目的 探討芪藶強(qiáng)心膠囊聯(lián)合左西孟旦注射液治療擴(kuò)張型心肌病心力衰竭的臨床療效。方法 選取2019年3月-2020年3月新野縣人民醫(yī)院收治的80例擴(kuò)張型心肌病心力衰竭患者，根據(jù)隨機(jī)數(shù)字表法中數(shù)字奇偶法將所有患者分為對(duì)照組和治療組，每組各40例。對(duì)照組患者泵注左西孟旦注射液，12 μg/kg，維持10 min后靜脈滴注，劑量為0.2 μg/（kg·min），滴注24 h，1次/周。治療組在對(duì)照組治療的基礎(chǔ)上口服芪藶強(qiáng)心膠囊，4粒/次，3次/d。兩組患者連續(xù)治療4周。觀察兩組臨床療效，比較兩組的心功能、心肌損傷指標(biāo)。結(jié)果 治療后，治療組總有效率（92.50%）高于對(duì)照組（72.50%），差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組左室射血分?jǐn)?shù)（LVEF）顯著升高，左心室收縮末期內(nèi)徑（LVESD）、左室舒張末期內(nèi)徑（LVEDD）明顯降低（P<0.05），且治療組LVEF高于對(duì)照組，LVESD、LVEDD低于對(duì)照組（P<0.05）。治療后，兩組心肌肌鈣蛋白I（cTnI）、N末端B型利鈉肽原（NT-proBNP）水平均明顯降低（P<0.05），且治療組cTnI、NT-ProBNP水平明顯低于對(duì)照組（P<0.05）。結(jié)論 芪藶強(qiáng)心膠囊聯(lián)合左西孟旦注射液治療擴(kuò)張型心肌病心力衰竭具有較好臨床療效，可提高心功能，減輕心肌損傷，安全性較好。

Objective To explore the effect of Qili Qiangxin Capsules combined with Levosimendan Injection in treatment of dilated cardiomyopathy complicated with heart failure. Methods Patients (80 cases) with dilated cardiomyopathy complicated with heart failure in Xinye County People's Hospital from March 2019 to March 2020 were randomly divided into control and treatment groups, and each group had 40 cases. Patients in the control group were pump injection administered with Levosimendan Injection, 12 μg/kg, after 10 min, intravenous drip was administered at a dose of 0.2 g/(kg·min) for 24 h, once weekly. Patients in the treatment group were po administered with Qili Qiangxin Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacies were evaluated, and cardiac function indexes and myocardial injury indexes in two groups were compared. Results After treatment, the total effective rate of the treatment group (92.50%) was higher than that of the control group (72.50%), and the difference was statistically significant (P<0.05). After treatment, the LVEF of two groups was significantly increased, but the LVESD and the LVEDD were significantly decreased (P<0.05). The LVEF of the treatment group was higher than that of the control group, but the LVESD and the LVEDD of the treatment group were lower than those of the control group (P<0.05). After treatment, the levels of cTnI and NT-Pro BNP in two groups were significantly decreased (P<0.05), and the levels of cTnI and NT-Pro BNP in the treatment group were significantly lower than those in the control group (P<0.05). Conclusion Qili Qiangxin Capsules combined with Levosimendan Injection has clinical curative effect in treatment of dilated cardiomyopathy complicated with heart failure, can improve cardiac function and reduce myocardial injury.

R972